The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 359:416-418 July 24, 2008 Number 4
NextNext

HIV Integrase Inhibitors — Out of the Pipeline and into the Clinic
Diane V. Havlir, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Steigbigel, R. T.
-Related Article
 by Cooper, D. A.
-PubMed Citation
Human immunodeficiency virus (HIV) infection has been transformed over the past two decades from a fatal to a chronic disease, because of combination antiretroviral therapy — a medical triumph.1 However, HIV has proven to be a masterful escape artist with regard to the pharmacologic agents strategically deployed to block its replication, and the counterpoint to the antiretroviral success story is one of drug resistance and toxicity. For a sizable number of patients who have developed or acquired highly drug-resistant HIV, suffering the ill effects of HIV disease is either a reality or a looming threat.

In most patients with highly . . . [Full Text of this Article]


Source Information

From the Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.